# Natalizumab (Tysabri) Re-Initiation of Dosing

> **NCT00297232** · PHASE3 · TERMINATED · sponsor: **Biogen** · enrollment: 1094 (actual)

## Conditions studied

- Relapsing-Remitting Multiple Sclerosis

## Interventions

- **DRUG:** Natalizumab

## Key facts

- **NCT ID:** NCT00297232
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-03
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 1094 (ACTUAL)
- **Last updated:** 2016-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00297232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00297232, "Natalizumab (Tysabri) Re-Initiation of Dosing". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00297232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*